Page last updated: 2024-11-13

ono-8430506

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ONO-8430506: an autotaxin inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID56597976
CHEMBL ID4649390
SCHEMBL ID14892670
MeSH IDM000598707

Synonyms (10)

Synonym
SCHEMBL14892670
ono-8430506
MS-28471
EX-A5185
1354805-08-5
HY-145344
bdbm50542080
CHEMBL4649390 ,
CS-0371631
AKOS040756675

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In this study, we showed that dosing rats with ONO-8430506 decreased intraurethral pressure accompanied by urethral relaxation."( A novel highly potent autotaxin/ENPP2 inhibitor produces prolonged decreases in plasma lysophosphatidic acid formation in vivo and regulates urethral tension.
Hayashi, A; Katoh, M; Kishikawa, K; Komichi, Y; Maeda, T; Matsumura, N; Mizuno, H; Nakade, S; Ohhata, A; Ota, H; Saga, H; Shibaya, M; Sugiyama, T; Takada, Y, 2014
)
0.66
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Ectonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)IC50 (µMol)0.01000.00111.095810.0000AID1658784
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (11)

Processvia Protein(s)Taxonomy
chemotaxisEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
immune responseEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
phospholipid catabolic processEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
positive regulation of epithelial cell migrationEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
vesicle-mediated transportEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
sphingolipid catabolic processEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
regulation of cell migrationEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
phosphatidylcholine catabolic processEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
cell motilityEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
positive regulation of lamellipodium morphogenesisEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
nucleic acid bindingEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
lysophospholipase activityEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
scavenger receptor activityEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
calcium ion bindingEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
zinc ion bindingEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
hydrolase activityEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
polysaccharide bindingEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
alkylglycerophosphoethanolamine phosphodiesterase activityEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
phosphodiesterase I activityEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
extracellular spaceEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
plasma membraneEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
extracellular spaceEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID1658802Volume of distribution at steady state in Sprague-Dawley rat at 0.3 mg/kg, iv administered as single dose by LC-MS/MS analysis2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658808Half life in Beagle dog at 0.3 mg/kg, iv administered as single dose by LC-MS/MS analysis2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658819In vivo inhibition of lysoPLD activity of ATX in SCID mouse plasma xenografted with human MDA-MB-231 cells at 100 mg/kg, po administered twice daily for 32 days in combination with paclitaxel at 20 mg/kg, ip three times weekly for 5 weeks and measured at 2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658784Inhibition of recombinant human ATX assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrs2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658813Oral bioavailability in Beagle dog at 1 mg/kg administered as single dose by LC-MS/MS analysis2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658820Volume of distribution at steady state in cynomolgus monkey at 0.3 mg/kg, iv administered as single dose by LC-MS/MS analysis2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658792Protein binding in human plasma measured after 4 hrs by LC-MS/MS analysis2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658814Oral bioavailability in Sprague-Dawley rat at 1 mg/kg administered as single dose by LC-MS/MS analysis2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658822Half life in cynomolgus monkey at 0.3 mg/kg, iv administered as single dose by LC-MS/MS analysis2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658804Half life in Sprague-Dawley rat at 1 mg/kg, po administered as single dose by LC-MS/MS analysis2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658800Half life in SCID mouse at 1 mg/kg, po administered as single dose by LC-MS/MS analysis2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658812Oral bioavailability in cynomolgus monkey at 1 mg/kg administered as single dose by LC-MS/MS analysis2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658805Clearance in Sprague-Dawley rat at 0.3 mg/kg, iv administered as single dose by LC-MS/MS analysis2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658801Cmax in Sprague-Dawley rat at 1 mg/kg, po administered as single dose by LC-MS/MS analysis2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658810Clearance in Beagle dog at 0.3 mg/kg, iv administered as single dose by LC-MS/MS analysis2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658799Cmax in SCID mouse at 1 mg/kg, po administered as single dose by LC-MS/MS analysis2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658803Half life in Sprague-Dawley rat at 0.3 mg/kg, iv administered as single dose by LC-MS/MS analysis2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658809Half life in Beagle dog at 1 mg/kg, po administered as single dose by LC-MS/MS analysis2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658818In vivo inhibition of lysoPLD activity of ATX in SCID mouse plasma xenografted with human MDA-MB-231 cells at 30 mg/kg, po administered twice daily for 32 days in combination with paclitaxel at 20 mg/kg, ip three times weekly for 5 weeks and measured at 12020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658815Antitumor activity against human MDA-MB-231 cells xenografted in SCID mouse assessed as tumor growth inhibition at 100 mg/kg, po administered twice daily for 32 days and measured on day 33 relative to control2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658816Potentiation of paclitaxel-induced antitumor activity against human MDA-MB-231 cells xenografted in SCID mouse assessed as tumor growth inhibition at 30 mg/kg, po administered twice daily for 32 days in combination with paclitaxel at 20 mg/kg, ip three ti2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658793Protein binding in rat plasma measured after 4 hrs by LC-MS/MS analysis2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658806Cmax in Beagle dog at 1 mg/kg, po administered as single dose by LC-MS/MS analysis2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658823Clearance in cynomolgus monkey at 0.3 mg/kg, iv administered as single dose by LC-MS/MS analysis2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658817Potentiation of paclitaxel-induced antitumor activity against human MDA-MB-231 cells xenografted in SCID mouse assessed as tumor growth inhibition at 100 mg/kg, po administered twice daily for 32 days in combination with paclitaxel at 20 mg/kg, ip three t2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658811Cmax in cynomolgus monkey at 1 mg/kg, po administered as single dose by LC-MS/MS analysis2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658807Volume of distribution at steady state in Beagle dog at 0.3 mg/kg, iv administered as single dose by LC-MS/MS analysis2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658798AUC in Sprague-Dawley rat at 0.5 mg/kg, po administered as single cassette dosing by LC-MS/MS analysis2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
AID1658791Inhibition of LysoPLD activity of ATX in human plasma assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrs2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (50.00)24.3611
2020's3 (50.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.35 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]